Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, announces that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022.